Skip to content
‹ Back to IndustriesHealthcare

Vital Spark, a Spark Biomedical Podcast: Neurostimulation for Opioid Withdrawal Relief

The last three years have seen a dramatic rise in opioid-related deaths. In 2018, there were 42,000 deaths related to opioids. That number rose 57% to 73,757 in the year-long period between April 2020 and April 2022. One of the primary reasons many keep using opioids is fear of withdrawal. In the first episode of…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share
Vital Spark, a Spark Biomedical Podcast: Neurostimulation for Opioid Withdrawal Relief

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The last three years have seen a dramatic rise in opioid-related deaths. In 2018, there were 42,000 deaths related to opioids. That number rose 57% to 73,757 in the year-long period between April 2020 and April 2022. One of the primary reasons many keep using opioids is fear of withdrawal. In the first episode of the Vital Spark series, Daniel Powell, CEO of Spark Biomedical, joined Host Daniel Litwin to explain his company’s alternative opioid withdrawal treatment approach.

Powell suggested that a critical aspect of helping individuals and their families is to provide up-to-date education, resources, and accurate information—which is why the company is launching its podcast VitalSpark. Powell stated, “Addiction normally is coming from a place of trauma, normally coming from a place of someone trying to heal but not have the resources, so they’re coping.” Spark is offering a treatment option and now adding resources to ensure patients and their families are armed with the best information possible.

Spark Biomedical offers a solution to supplement traditional drug-based opioid withdrawal therapies through its wearable neurostimulation device, the Sparrow™Therapy System. This drug-free treatment option uses transcutaneous auricular neurostimulation (tAN®)and is applied to the skin on and around the ear tostimulatethe trigeminal and Vagus nerves that surface just below the skin in these areas. Worn by patients thorough the five-to-ten-day withdrawal period, this FDA-cleared treatment option has been clinically proven to significantly reduce acute withdrawal symptoms within 30 to 60 minutes of active use.

The company also has its sights set on understanding how its Sparrow Therapy wearable neurostimulation solution can impact PTSD and improve cognition, among other profound effects.More specifically,Spark recently kicked off a Phase II clinical trial to study the effect wearable neurostimulation can have on long-term addiction.Powell stated, “The overall goal has always been to be a recovery tool for long-term addiction.” He added, “After you get through withdrawal and what we’re starting clinical trials on, is can we manage your cravings, your depression, your anxiety, the triggers for relapse and actually fix the curve and start to bend the curve of addiction in America?”

Powell’s advice for supporters of addicted individuals? Don’t try to fix them. Have compassion for them and their journey. And, if they need support for opioid withdrawal, have them ask their care provider about the Sparrow Therapy System.”For more information on this topic, follow Spark Biomedical’s LinkedIn account and visit sparkbiomedical.com.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Berg Insight expects 160 million home medical monitors in care programs by 2030

Berg Insight expects 160 million home medical monitors in care programs by 2030

Prescribed connected home medical monitors are forecast to grow from 92.7 million in 2025 to 159.7 million by 2030. The fastest growth is in diabetes, remote ECG and medication compliance, categories spread across many suppliers. Clinical value increasingly depends on combining data from different devices.

  • 01159.7 million prescribed home medical monitors expected by 2030, growing at 11.5 percent annually from 92.7 million in 2025.
  • 02Sleep therapy is the largest connected segment, followed by diabetes with 19.5 million connections at end of 2025, with fastest future growth in diabetes, remote ECG and medication compliance monitoring.
  • 03Clinical value increasingly depends on integrating data across devices into workflows: vendors combine hardware, software, analytics and interoperability with existing healthcare systems.

Oct 26, 2026

Zocdoc's first acquisition in nearly 20 years is an insurance checker

Zocdoc's first acquisition in nearly 20 years is an insurance checker

Zocdoc has bought Sohar Health, its first acquisition in nearly 20 years. Sohar's software finds and verifies a patient's insurance coverage from a name and birth date. Zocdoc wants that check to work across its Care Access Network, which lets insurers, consumer apps and AI tools embed Zocdoc's clinician search and scheduling on their own websites and apps.

  • 01After nearly 20 years without an acquisition, Zocdoc's first purchase is the insurance check that sits between a patient's search and a booked appointment.
  • 02For practices that pay Zocdoc per booking, the sharper question is how often coverage verified at booking matches what the front desk confirms at check-in.

Oct 24, 2026

The physical exam splits into parts, and each goes remote at its own pace

The physical exam splits into parts, and each goes remote at its own pace

One weak link in virtual physical exams is patient technique, since home readings depend on how patients take them.

  • 01Charting what a patient could not do for lack of home equipment is part of the exam record, and federal telehealth guidance ties that documentation to coding and billing.
  • 02Remote exams fit best where home data already accumulates: a week of home blood pressure readings or continuous glucose data shows what a single office reading cannot.

Oct 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512